Modular Benzofuran TRPM3 Antagonists for Pharmacokinetic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant medical need for novel, alternative, and/or better therapeutics for TRPM3 mediated disorders, particularly for pain such as inflammatory pain, with a focus on compounds that have good potency, low side-effects, and favorable pharmacokinetic or -dynamic properties.
Innovation Solution
Development of benzofuran derivatives that act as TRPM3 antagonists, which can be used to prevent or treat TRPM3 mediated disorders, specifically pain and inflammatory hypersensitivity, through a method involving the reaction of benzoquinone with a suitable ketoester or enamine derivative, followed by substitution and coupling with a suitable amine to form amide derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TRPM3 antagonists are used, then some pain relief effect is achieved, but they have high side-effects and poor pharmacokinetic properties
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of TRPM3 antagonists through varying substituents (R1, R2, R3, R4, R5, R6, R7, R8) at different positions of the core framework. This includes changing heteroatoms (N, O, S), alkyl groups, aryl groups, and their configurations to optimize the balance between therapeutic efficacy and side-effect profile, achieving improved potency and pharmacokinetic properties while reducing toxicity
Solution Approach 2:
The patent employs composite material principles by combining the core TRPM3 antagonist framework with various functional groups and heterocyclic systems. The compounds integrate multiple structural elements (e.g., piperazine rings, pyridine groups, fluorinated alkyl chains) to create molecules with enhanced therapeutic index, where each component contributes specific pharmacological properties that collectively improve efficacy while minimizing adverse effects
2Reliability
If existing TRPM3 antagonists are used, then some pain relief effect is achieved, but they have unfavorable pharmacokinetic or -dynamic properties
Solution Approach 1:
The patent optimizes pharmacokinetic properties through parameter changes in molecular structure, including adjusting lipophilicity via alkyl and aryl substituents, modifying molecular weight and size, and altering metabolic stability through strategic placement of heteroatoms and functional groups. These changes improve absorption, distribution, metabolism, and excretion (ADME) characteristics while maintaining potent TRPM3 antagonism
3Reliability
If novel TRPM3 antagonists are developed, then better therapeutic properties are achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex TRPM3 antagonist into modular components: a core framework structure and interchangeable substituent groups (R1-R8). This modular approach allows systematic optimization of individual regions (e.g., basic nitrogen-containing moiety, aromatic groups, heterocyclic rings) while maintaining overall molecular architecture, facilitating structure-activity relationship studies and rational drug design
Data Source
AI summary
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.